Top

Gepubliceerd in:

01-02-2010 | review article

Recurrent and founder mutations in the Netherlands

Extensive clinical variability in Marfan syndrome patients with a single novel recurrent fibrillin-1 missense mutation

Auteurs: J. J. J. Aalberts, A. G. Schuurman, G. Pals, B. J. C. Hamel, G. Bosman, Y. Hilhorst-Hofstee, D. Q. C. M. Barge-Schaapveld, B. J. M. Mulder, M. P. van den Berg, J. P. van Tintelen

Gepubliceerd in: Netherlands Heart Journal | Uitgave 2/2010

Abstract

Background/Methods. Marfan syndrome (MFS) is a heritable connective tissue disorder usually caused by a mutation in the fibrillin 1 (FBN1) gene. Typical characteristics of MFS that have been described include dolichostenomelia, ectopia lentis and aortic root dilatation. However, there is great clinical variability in the expression of the syndrome’s manifestations, both between and within families. Here we discuss the clinical variability of MFS by describing a large fourgeneration Dutch family with MFS.

Results. Nineteen individuals of one family with a single missense FBN1 mutation (c.7916A>G) were identified. The same mutation was found in one unrelated person. Clinical variability was extensive and not all mutation carriers fulfilled the diagnostic criteria for MFS. Some patients only expressed mild skeletal abnormalities, whereas aortic root dilation was present in eight patients, an acute type A aortic dissection was recorded in two other patients, and a mitral valve prolapse was present in eight patients. In some patients cardiac features were not present on initial screening, but did however develop over time.

Conclusion. MFS is a clinically highly variable syndrome, which means a meticulous evaluation of suspected cases is crucial. Mutation carriers should be re-evaluated regularly as cardiovascular symptoms may develop over time. (Neth Heart J 2010;18:85–9.)

vorige artikel Measure twice, cut once: pitfalls in the diagnosis of supraventricular tachycardia

volgende artikel Cardiac PET-CT: advanced hybrid imaging for the detection of coronary artery disease

De Paepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet. 1996;62:417–26.

Rand-Hendriksen S, Lundby R, Tjeldhorn L, Andersen K, Offstad J, Semb SO, et al. Prevalence data on all Ghent features in a cross-sectional study of 87 adults with proven Marfan syndrome. Eur J Hum Genet. 2009; ahead of print: 1–9.

De Backer J, Loeys B, Leroy B, Coucke P, Dietz H, De Paepe A. Utility of molecular analyses in the exploration of extreme intrafamilial variability in the Marfan syndrome. Clin Genet. 2007;72:188–98.

Giusti B, Porciani MC, Brunelli T, Evangelisti L, Fedi S, Gensini GF, et al. Phenotypic variability of cardiovascular manifestations in Marfan syndrome. Possible role of hyperhomocysteinemia and C677T MTHFR gene polymorphism. Eur Heart J. 2003;24:2038–45.

Hutchinson S, Furger A, Halliday D, Judge DP, Jefferson A, Dietz HC, et al. Allelic variation in normal human FBN1 expression in a family with Marfan syndrome: a potential modifier of phenotype? Hum Mol Genet. 2003;12:2269–76.

Pearson GD, Devereux R, Loeys B, Maslen C, Milewicz D Pyeritz R. Report of the National Heart, Lung, and Blood institute and National Marfan Foundation Working Group on research in Marfan syndrome and related disorders. Circulation. 2008;118:785–91.

Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai YL, Corson GM, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991;352:337–9.

Gray JR, Bridges AB, West RR, McLeish L, Stuart AG, Dean JCS, et al. Life expectancy in British Marfan syndrome populations. Clin Genet. 1998;54:124–8.

Mizuguchi T, Collod-Beroud G, Akiyama T, Abifadel M, Harada N, Morisaki T, et al. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet. 2004;36:855–60.

10.

Singh KK, Rommel K, Mishra A, Karck M, Haverich A, Schmidtke J, et al. TGFBR1 and TGFBR2 mutations in patients with features of Marfan syndrome and Loeys Dietz syndrome. Hum Mutat. 2006;27:770–7.

11.

Sakai H, Visser R, Ikegawa S, Ito E, Numabe H, Watanabe Y, et al. Comprehensive genetic analysis of four relevant genes in 49 patients with Marfan syndrome or Marfan-related phenotypes. Am J Med Genet. 2006;140:1719–25.

12.

Mátyás G, De Paepe A, Halliday D, Boileau C, Pals G, Steinmann B. Evaluation and application of denaturing HPLC for mutation detection in Marfan syndrome: Identification of 20 novel mutations and two novel polymorphisms in the FBN1 gene. Hum Mutat. 2002;19:443–56.

13.

Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, et al. Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome. Nat Genet. 2003;33:407–11.

14.

Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci. 2003;116:217–24.

15.

Ng CM, Cheng A, Myers LA, Martinez-Murillo F, Jie C, Bedja D, et al. TGF-beta dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest. 2004;114:1586–92.

16.

Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312:117–21.

17.

Faivre L, Masurel-Paulet A, Collod-Béroud G, Callewaert BL, Child AH, Stheneur C, et al. Clinical and molecular study of 320 children with Marfan syndrome and related type I fibrillinopathies in a series of 1009 probands with pathogenic FBN1 mutations. Pediatrics. 2009;123:391–8.

18.

Faivre L, Collod-Béroud G, Child A, Callewaert B, Loeys BL, Binquet C, et al. Contribution of molecular analyses in diagnosing Marfan syndrome and type I fibrillinopathies: an international study of 1009 probands. J Med Genet. 2008;45:384–90.

19.

Robinson PN, Arteaga-Solis E, Baldock C, Collod-Béroud G, Booms P, De Paepe A, et al. The molecular genetics of Marfan syndrome and related disorders. J Med Genet. 2006;43:769–87.

20.

Collod-Béroud G, Le Bourdelles S, Ades L, Ala-Koko L, Booms P, Child A, et al. Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database. Hum Mutat. 2003;22:198–208.

21.

22.

Van Dijk FS, Hamel BC, Hilhorst-Hofstee Y, Mulder BJM, Timmermans J, Pals G, et al. Compound-heterozygous Marfan syndrome. Eur J Med Genet. 2009;52:1–5.

Titel: Recurrent and founder mutations in the Netherlands
Extensive clinical variability in Marfan syndrome patients with a single novel recurrent fibrillin-1 missense mutation
Auteurs: J. J. J. Aalberts
A. G. Schuurman
G. Pals
B. J. C. Hamel
G. Bosman
Y. Hilhorst-Hofstee
D. Q. C. M. Barge-Schaapveld
B. J. M. Mulder
M. P. van den Berg
J. P. van Tintelen
Publicatiedatum: 01-02-2010
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Netherlands Heart Journal / Uitgave 2/2010
Print ISSN: 1568-5888
Elektronisch ISSN: 1876-6250
DOI: https://doi.org/10.1007/BF03091743

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 2/2010

Cardiac surgery in patients irradiated for Hodgkin’s lymphoma

An in vivo comparison of radiofrequency cardiac lesions formed by standard and magnetically steered 4 mm tip catheters

Postural electrocardiographic abnormalities

Evaluation of global left ventricular function assessment of non-fluorescent electromechanical endocardial mapping compared with biplane left ventricular contrast angiography

Measure twice, cut once: pitfalls in the diagnosis of supraventricular tachycardia

Measure twice, think three times, cut once